4-{4-[1,1-difluoro-1-(ethoxycarbonyl)methyl]phenoxy}-N-methylthieno[2,3-c]pyridine-2-carboxamide | 251996-76-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-{4-[1,1-difluoro-1-(ethoxycarbonyl)methyl]phenoxy}-N-methylthieno[2,3-c]pyridine-2-carboxamide
• 英文别名: 4-[4-(1,1-Ddifluoro-2-ethoxy-2-oxoethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide；4-[4-(1,1-Difluoro-2-ethoxy-2-oxoethyl)phenoxy]-n-methylthieno[2,3-c]pyridine-2-carboxamide；ethyl 2,2-difluoro-2-[4-[2-(methylcarbamoyl)thieno[2,3-c]pyridin-4-yl]oxyphenyl]acetate
• CAS: 251996-76-6
• 化学式: C₁₉H₁₆F₂N₂O₄S
• 分子量: 406.41
• InChiKey: INCXJBNGENITFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  28
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4-{4-[1,1-difluoro-1-(ethoxycarbonyl)methyl]phenoxy}-N-methylthieno[2,3-c]pyridine-2-carboxamide 在 sodium tetrahydroborate 、 三氟乙酸 作用下， 以 甲醇 为溶剂， 以94%的产率得到4-[4-(1,1-difluoro-2-hydroxyethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide
  参考文献：
  名称：

  Cell adhesion-inhibiting antiinflammatory compounds

  摘要：

  具有I式化学式的化合物对于治疗炎症是有用的。还公开了包含I式化合物的药物组合物，以及在哺乳动物中抑制/治疗炎症性疾病的方法。

  公开号：

  US06232320B1
• 作为产物：
  描述：

  3,5-Bis(4-iodophenoxy)pyridine-4-carbaldehyde 在 lithium hydroxide 、 铜 、 caesium carbonate 、 1-羟基苯并三唑一水物 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 苯酚 作用下， 以 四氢呋喃 、 二甲基亚砜 、 N,N-二甲基甲酰胺 为溶剂， 反应 35.5h， 生成 4-{4-[1,1-difluoro-1-(ethoxycarbonyl)methyl]phenoxy}-N-methylthieno[2,3-c]pyridine-2-carboxamide
  参考文献：
  名称：

  Selective Inhibition of ICAM-1 and E-Selectin Expression in Human Endothelial Cells. 2. Aryl Modifications of 4-(Aryloxy)thieno[2,3-c]pyridines with Fine-Tuning at C-2 Carbamides

  摘要：

  The elevated expression of cell adhesion molecules (CAMs) on the lumenal surface of vascular endothelial cells is a critical early event in the complex inflammatory process. The adhesive interactions of these CAMs that include E-selectin, ICAM-1, and VCAM-1 with their counterreceptors on leukocytes, such as integrins of the alpha (L)beta (2) family, result in migration of the leukocytes to the site of inflammation and cause tissue injury. Pharmaceutical agents that could suppress the induced expression of one or more of these cell adhesion molecules would provide a novel mechanism to attenuate the inflammatory responses associated with chronic inflammatory diseases. A-205804 (1), a potent and selective inhibitor of the induced expression of E-selectin and ICAM-1 over VCAM-1, was further modified with emphasis at the C-4 and C-2 positions to identify a more potent drug candidate with a good pharmacokinetic profile and physical properties. Replacement of the C-4 sulfur linkage in I with an oxygen atom eliminated one of the two major metabolites for this lead molecule. The para-position of the 4-phenoxy group of the thieno[2,3-c]pyridine lead is found to be very critical for a higher in vitro potency and selectivity of E-selectin and ICAM-1 over VCAM-1 expression. This position is presumably close to the solvent-accessible region of the target protein-inhibitor complex. An attempt to install a water-solubilizing group at the para-position of the phenoxy group to increase the aqueous solubility of this lead series through various linkages failed to provide an ideal inhibitor. Only small substituents such as fluorine are tolerated at the meta- and ortho-positions of the 4-phenoxy to retain a good in vitro potency. Bromo, trifluoromethyl, pyrazol-1-yl, and imidazol-1-yl are among the better substituents at the para-position. With fine-tuning at the C-2 position we discovered a series of very potent (IC50 < 5 nM for ICAM-1) and selective (> 200-fold vs VCAM-1) inhibitors with a good pharmacokinetic profile. Demonstrated efficacy in a rat rheumatoid arthritis model and in a mice asthma model with selected compounds is also reported.

  DOI：

  10.1021/jm0101702

文献信息

• US6232320B1
  申请人：——

  公开号：US6232320B1

  公开（公告）日：2001-05-15